0 stringlengths 16 494 | embeddings listlengths 384 384 |
|---|---|
tions 7.33 and 7.34, people with diabetes\nwearing diabetes devices should be sup-ported to continue them in an inpatientsetting if they are assessed and deemed\ncompetent to perform self-care and proper\nsupervision is available.\nSTANDARDS FOR SPECIAL\nSITUATIONS\nEnteral/Parenteral Feedings\nFor individuals receivin... | [
-0.04780758172273636,
-0.014921080321073532,
-0.0031899181194603443,
-0.0018665818497538567,
-0.08845263719558716,
-0.012495482340455055,
0.08629021048545837,
0.08974796533584595,
-0.05435938015580177,
-0.05809991434216499,
0.014106374233961105,
0.043627459555864334,
-0.0814981684088707,
0... |
For individuals receiving enteral or parenteral\nfeedings who require insulin, the insulin or-ders should include coverage of basal, pran-\ndial, and correctional needs (115,122,123).\nIt is essential that people with type 1 diabe-tes continue to receive basal insulin even iffeedings are discontinued.\nMost adults rece... | [
-0.025999093428254128,
0.03238006681203842,
-0.03594408184289932,
-0.02547200582921505,
-0.026301447302103043,
-0.004531092941761017,
0.10365993529558182,
0.04035963490605354,
-0.04531567171216011,
-0.01863745227456093,
0.05780618637800217,
0.02514479123055935,
-0.06654497236013412,
0.0193... |
Most adults receiving basal insulin\nshould continue with their basal dose,\nwhile the insulin dose for the total daily\nnutritional component may be calculatedas 1 unit of insulin for every 10 –15 g of\ncarbohydrate in the enteral and paren-\nteral formulas. Commercially available | [
0.03169809654355049,
0.0021537644788622856,
-0.05838579684495926,
-0.008134478703141212,
-0.04674729332327843,
-0.024413825944066048,
0.09223482012748718,
0.07132010906934738,
-0.03141622990369797,
0.005369642749428749,
0.03065324015915394,
-0.020286066457629204,
-0.016122113913297653,
0.0... |
teral formulas. Commercially available\ncans of enteral nutrition contain variableamounts of carbohydrates and may beinfused at different rates.\nAll of this must be considered when | [
-0.02183188684284687,
-0.05208506062626839,
-0.044518545269966125,
0.0028836310375481844,
-0.04089844971895218,
0.05254311114549637,
-0.04245160520076752,
0.09437379986047745,
0.04684703052043915,
-0.03487919270992279,
0.024739786982536316,
-0.0931842029094696,
-0.07038668543100357,
0.0177... |
All of this must be considered when\ncalculating insulin doses to cover the nu-tritional component of enteral nutrition(116). Giving NPH insulin two or threetimes daily (every 8 or 12 h) to cover indi-vidual requirements is a reasonable op-\ntion. Adjustments in insulin doses should | [
0.011193455196917057,
0.03337406367063522,
-0.047590598464012146,
-0.03794887661933899,
-0.06967062503099442,
-0.03385048732161522,
0.026550300419330597,
0.041905686259269714,
-0.0952630266547203,
-0.020123708993196487,
-0.020175212994217873,
-0.027869882062077522,
-0.0511530265212059,
0.0... |
tion. Adjustments in insulin doses should\nbe made frequently. Correctional insulinshould also be administered subcutane-ously every 6 h with regular human insu-\nlin. If enteral nutrition is interrupted, a | [
-0.001575426897034049,
0.014513494446873665,
-0.10963650047779083,
-0.0011151130311191082,
-0.07024041563272476,
-0.011742527596652508,
0.04884478822350502,
0.040020380169153214,
-0.03276955336332321,
-0.021480191498994827,
0.05082850903272629,
0.05917095020413399,
-0.06277504563331604,
0.... |
lin. If enteral nutrition is interrupted, a\ndextrose infusion should be started im-mediately to prevent hypoglycemia andS300 Diabetes Care in the Hospital Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
-0.05107107013463974,
-0.07057332247495651,
-0.04354279488325119,
0.029897866770625114,
0.05325371026992798,
0.05471564084291458,
0.06536956131458282,
0.07335686683654785,
0.009068748913705349,
-0.012977398000657558,
0.012741416692733765,
0.02972481958568096,
-0.07982230186462402,
-0.00277... |
to allow time to determine more appro-\npriate insulin doses.\nFor adults receiving enteral bolus feed-\nings, approximately 1 unit of regular humaninsulin or rapid-acting insulin per every10–15 g of carbohydrate should be given | [
-0.014699814841151237,
0.027325015515089035,
-0.0809265598654747,
0.011424912139773369,
-0.029134362936019897,
-0.03275826945900917,
0.0918797105550766,
0.050290413200855255,
0.00109387980774045,
-0.03618108853697777,
0.014916602522134781,
0.017112908884882927,
-0.05509409308433533,
0.0091... |
subcutaneously before each feeding. To mit-igate any hyperglycemia, correctional insu-lin should be added as needed before eachfeeding.\nIn individuals receiving nocturnal tube\nfeeding, NPH insulin administered alongwith the initiation of the feeding is a rea-sonable approach to cover this nutritionalload.\nFor indivi... | [
-0.02571592479944229,
0.027393508702516556,
-0.08448293805122375,
0.00349457492120564,
-0.05241909995675087,
0.03833033889532089,
0.039192408323287964,
0.03984268009662628,
-0.06872931122779846,
-0.01355179212987423,
0.0733855813741684,
0.041977111250162125,
-0.03995687887072563,
0.0005221... |
For individuals receiving continuous pe-\nripheral or central parenteral nutrition,human regular insulin may be added tothe solution, particularly if >20 units of\ncorrectional insulin have been required inthe past 24 h. A starting dose of 1 unit of\nregular human insulin for every 10 g of | [
-0.004920965526252985,
0.008405853994190693,
-0.024274414405226707,
-0.024387681856751442,
-0.04089497774839401,
-0.03141886368393898,
0.11278080195188522,
0.08887145668268204,
-0.01967068389058113,
-0.01682637631893158,
0.04495690017938614,
0.02875717543065548,
-0.02207048423588276,
0.042... |
dextrose has been recommended (105)and should be adjusted daily in the solu-tion. Adding insulin to the parenteral nu-trition bag is the safest way to preventhypoglycemia if the parenteral nutrition isstopped or interrupted. Correctional insu-lin should be administered subcutane-ously to address any hyperglycemia. | [
-0.09187574684619904,
-0.03252442926168442,
-0.06773898750543594,
-0.03660077974200249,
0.004854071419686079,
0.006037733983248472,
0.08121117204427719,
0.0705956295132637,
-0.07471068948507309,
-0.006493460852652788,
0.015315048396587372,
0.06281343847513199,
-0.07955469936132431,
0.01750... |
Because continuous enteral or parenteral | [
0.04416382312774658,
-0.09358782321214676,
0.047064729034900665,
-0.0015913539100438356,
-0.029886312782764435,
-0.005026933271437883,
-0.004046499729156494,
0.09148067981004715,
0.15334632992744446,
0.011751708574593067,
0.026493892073631287,
0.041269559413194656,
-0.03117462247610092,
0.... |
nutrition results in a continuous postpran-dial state, efforts to bring blood glucoselevels to below 140 mg/dL (7.8 mmol/L)substantially increase the risk of hypoglyce-mia in these individuals. For full enteral/parenteral feeding guidance, please referto randomized controlled trials detailingthis topic (122,124).\nGluc... | [
0.02917570061981678,
0.05618107318878174,
-0.03161878511309624,
0.019643105566501617,
-0.11508902907371521,
-0.010580386035144329,
0.009054732508957386,
0.1268921047449112,
-0.06768988072872162,
-0.04516643285751343,
-0.014941896311938763,
0.07483666390180588,
-0.07156907767057419,
-0.0187... |
Glucocorticoid Therapy\nThe prevalence of consistent use of gluco-corticoid therapy in hospitalized individualscan approach 10 –15%, and these medica-\ntions can induce hyperglycemia in 56 –86%\nof these individuals with and without\npreexisting diabetes (125 –127). If left un-\ntreated, this hyperglycemia increases mo... | [
-0.034566231071949005,
0.03665030747652054,
-0.04408003389835358,
0.03381362184882164,
-0.11040651053190231,
0.013089286163449287,
0.05670144036412239,
0.09235665202140808,
-0.07056873291730881,
-0.004920582287013531,
-0.00993009191006422,
0.10639150440692902,
-0.0700378268957138,
-0.06112... |
treated, this hyperglycemia increases mor-\ntality and morbidity risk, e.g., infectionsand cardiovascular events. Glucocorticoidtype and duration of action must be con-sidered in determining appropriate insulintreatments. Daily-ingested intermediate-acting glucocorticoids such as prednisonereach peak plasma levels in 4... | [
0.011731211096048355,
0.0572550967335701,
-0.026109550148248672,
0.04863055795431137,
-0.09697822481393814,
0.0240563303232193,
0.02367759682238102,
0.09774476289749146,
-0.0802372545003891,
0.04148431494832039,
-0.05108100548386574,
0.10312486439943314,
-0.06800160557031631,
-0.0145658226... |
but have pharmacologic actions that canlast throughout the day. Individuals placedon morning steroid therapy have dispro-portionate hyperglycemia during the daybut frequently reach blood glucose goals\novernight regardless of treatment (125). In | [
-0.023251719772815704,
0.07590232789516449,
-0.0221016313880682,
0.010289587080478668,
-0.045062463730573654,
-0.055892765522003174,
0.0374658927321434,
0.07371233403682709,
-0.0422494076192379,
-0.0662507638335228,
-0.06835715472698212,
0.10133201628923416,
-0.06649851053953171,
0.0220538... |
overnight regardless of treatment (125). In\nindividuals on once- or twice-daily steroids,administering NPH insulin is a standardapproach. NPH is usually administered inaddition to daily basal-bolus insulin or inaddition to oral glucose-lowering medica-\ntions, depending on the type of diabetes | [
0.01226029172539711,
0.07035919278860092,
-0.07633735984563828,
0.04447602108120918,
-0.047895099967718124,
-0.04724566265940666,
0.00976100005209446,
0.07370763272047043,
-0.03372817859053612,
-0.03453690558671951,
-0.0218924880027771,
0.07247491925954819,
-0.05965244024991989,
0.04024791... |
tions, depending on the type of diabetes\nand recent diabetes medication prior tostarting steroids. Because NPH actionpeaks about 4 –6 h after administration, it\nis recommended that it be administered\nconcomitantly with intermediate-acting | [
-0.011033483780920506,
-0.030855761840939522,
-0.11273258179426193,
0.005776281468570232,
-0.09127049148082733,
0.002484939992427826,
0.04227016493678093,
0.13512533903121948,
-0.006569491699337959,
0.0022486811503767967,
-0.003793784650042653,
0.09762711822986603,
-0.07226227223873138,
0.... |
concomitantly with intermediate-acting\nsteroids (129). For long-acting glucocorti-coids such as dexamethasone and multi-dose or continuous glucocorticoid use,long-acting basal insulin may be requiredto manage fasting blood glucose levels\n(53,130). For higher doses of glucocorti- | [
-0.02097930572926998,
-0.0020458586513996124,
-0.09624093770980835,
-0.012416986748576164,
-0.10421301424503326,
-0.001548089669086039,
0.02055111713707447,
0.07993869483470917,
-0.07409030199050903,
-0.013337367214262486,
0.039257895201444626,
0.07170650362968445,
-0.06584975123405457,
0.... |
(53,130). For higher doses of glucocorti-\ncoids, increasing doses of prandial (if eat-ing) and correction insulin, sometimes asmuch as 40 –60% or more, are often\nneeded in addition to basal insulin(131,132). A retrospective study found\nthat increasing the ratio of insulin to | [
0.007034634239971638,
0.010214563459157944,
-0.11670618504285812,
0.031089290976524353,
-0.09643338620662689,
-0.020109260454773903,
0.0615236796438694,
0.10777808725833893,
-0.04990321770310402,
0.004691679496318102,
0.06707988679409027,
0.08607961237430573,
-0.05112350732088089,
-0.02466... |
that increasing the ratio of insulin to\nsteroids was positively associated withimproved time in range (70 –180 mg/dL);\nhowever, there was an increase in hypo-glycemia (133). If insulin orders are initi-ated, daily adjustments based on levels\nof glycemia and anticipated changes in | [
0.003999670036137104,
0.05359583720564842,
-0.07606970518827438,
0.039704687893390656,
-0.021287089213728905,
0.006256777327507734,
0.026324795559048653,
0.1043190285563469,
-0.05415834113955498,
-0.023816224187612534,
0.010957359336316586,
0.053904615342617035,
-0.018891794607043266,
-0.0... |
of glycemia and anticipated changes in\ntype, dosages, and duration of glucocor-ticoids, along with POC blood glucosemonitoring, are critical to reducing hypo-glycemia and hyperglycemia.\nPerioperative Care\nI ti se s t i m a t e dt h a tu pt o2 0 %o fi n d i v i d u -als undergoing general surgery have dia-\nbetes, an... | [
-0.03198126703500748,
0.022919822484254837,
-0.060329508036375046,
0.0158645361661911,
-0.12356133759021759,
-0.035123784095048904,
0.052671581506729126,
0.09405693411827087,
-0.033081717789173126,
-0.009799225255846977,
0.0013879594625905156,
0.09080833941698074,
-0.06266649067401886,
-0.... |
betes, and 23 –60% have prediabetes or\nundiagnosed diabetes. Surgical stress and\ncounterregulatory hormone release in-crease the risk of hyperglycemia as wellas mortality, infection, and length of stay(134– 136). There are little data available | [
0.03924107924103737,
0.0020186288747936487,
-0.047064170241355896,
0.08402751386165619,
-0.0313936211168766,
0.022002842277288437,
0.06755285710096359,
0.0336134247481823,
-0.030856400728225708,
0.049670811742544174,
-0.02991684339940548,
0.03139543905854225,
-0.07713544368743896,
0.028857... |
to guide care of people with diabetesthrough the perioperative period. To reducesurgical risk in people with diabetes, someinstitutions (135,137,138) have A1C cutoffsfor elective surgeries, and some have devel-oped optimization programs to lower A1C\nprior to surgery (134,135,137,138).\nThe following approach (134,135,... | [
-0.03856674209237099,
0.04152583330869675,
-0.015056276693940163,
-0.015437791123986244,
-0.11480029672384262,
0.009902930818498135,
0.021976949647068977,
0.0892440527677536,
-0.015410738065838814,
-0.002258861903101206,
-0.03259778767824173,
0.09862540662288666,
-0.03735395893454552,
-0.0... |
The following approach (134,135,137)\nmay be considered:\n1. A preoperative risk assessment should\nbe performed for people with diabe-\ntes who are at high risk for ischemicheart disease and those with auto-\nnomic neuropathy or renal failure.\n2 . T h eA 1 Cg o a lf o re l e c t i v es u r g e r i e s\nshould be <8% ... | [
0.028789449483156204,
0.005388636142015457,
-0.0028854000847786665,
-0.048143427819013596,
-0.08489983528852463,
-0.01686267741024494,
-0.013122429139912128,
0.12075884640216827,
-0.06299802660942078,
0.004136682953685522,
0.0376240573823452,
-0.002849278738722205,
-0.023015400394797325,
0... |
should be <8% (<63.9 mmol/L) when-\never possible.\n3. The blood glucose goal in the periopera-\ntive period should be 100 –180 mg/dL\n(5.6–10.0 mmol/L) (135) within 4 h\nof the surgery. CGM should not be\nused alone for glucose monitoring dur-\ning surgery (138).\n4. Metformin should be held on the\nday of surgery.\n5... | [
-0.041980937123298645,
0.022172288969159126,
-0.06805817037820816,
-0.05088892951607704,
-0.0749037116765976,
-0.048820942640304565,
-0.04272031411528587,
0.11031398177146912,
-0.05058397352695465,
-0.007899848744273186,
-0.017692742869257927,
-0.025495871901512146,
-0.10551625490188599,
0... |
day of surgery.\n5. SGLT2 inhibitors should be discon-\ntinued 3 –4 days before surgery.\n6. Hold other oral glucose-lowering agents\nthe morning of surgery or procedureand give one-half of NPH dose or75–80% doses of long-acting analog in-\nsulin or adjust insulin pump basal ratesbased on the type of diabetes and clini... | [
-0.0265800878405571,
0.024828648194670677,
-0.020204251632094383,
-0.0017076422227546573,
-0.05201024189591408,
-0.0575275644659996,
-0.016949035227298737,
0.06110275909304619,
-0.03220285102725029,
-0.018207842484116554,
-0.0032994041685014963,
0.07303930819034576,
-0.05488463118672371,
0... |
7. Monitor blood glucose at least every\n2–4 h while the individual takes noth-\ning by mouth and dose with short- orrapid-acting insulin as needed.\n8. There are little data on the safe use\nand/or in fluence of GLP-1 receptor\nagonists on glycemia and delayedgastric emptying in the perioperativeperiod.\n9. Stricter pe... | [
-0.034673575311899185,
0.06222410127520561,
-0.07035224884748459,
-0.012481766752898693,
-0.04444558545947075,
0.019042935222387314,
0.07797519117593765,
0.08138149976730347,
-0.07211744785308838,
0.01821911334991455,
-0.007823586463928223,
0.01378101296722889,
-0.1429983228445053,
0.04450... |
9. Stricter perioperative glycemic goals\nare not advised, as perioperative glyce-mic goals stricter than 80 –180 mg/dL\n(4.4–10.0 mmol/L) may not improve\noutcomes and are associated withmore hypoglycemia (137).\n10. Compared with usual dosing, a reduc-\ntion by 25% of basal insulin given theevening before surgery is ... | [
0.03276616707444191,
0.03138350695371628,
-0.03363616019487381,
-0.017545154318213463,
-0.06959100812673569,
-0.004540834575891495,
0.09457843005657196,
0.10258570313453674,
-0.11081662774085999,
-0.030503952875733376,
-0.007631795480847359,
0.02387283742427826,
-0.04469325765967369,
0.000... |
to achieve perioperative blood glucose\ngoals with a lower risk for hypoglyce-mia (139).\n11. In individuals undergoing noncardiac\ngeneral surgery, basal insulin pluspremeal short- or rapid-acting insulin(basal-bolus) coverage has been\nassociated with improved glycemic out-\ncomes and lower rates of perioperativecomp... | [
-0.03183482587337494,
0.07981488853693008,
-0.0694858729839325,
0.020959770306944847,
-0.0360647551715374,
0.004174689296633005,
0.05014513432979584,
0.06400373578071594,
-0.0350998155772686,
-0.023489754647016525,
0.0036610630340874195,
0.07743189483880997,
-0.06610431522130966,
-0.070754... |
active, correction-only short- or rapid-\nacting insulin coverage alone with nobasal insulin dosing (63,134,135).\nDiabetic Ketoacidosis and\nHyperglycemic Hyperosmolar State\nThere is considerable variability in the\npresentation of DKA and HHS, ranging\nfrom euglycemia or mild hyperglycemia | [
0.004380426369607449,
0.061103612184524536,
-0.0876397117972374,
0.030887821689248085,
-0.08910984545946121,
-0.02487083338201046,
0.03876274824142456,
0.0784439966082573,
-0.015355996787548065,
-0.011809968389570713,
0.03224509209394455,
0.0005846848944202065,
-0.10984066873788834,
-0.021... |
from euglycemia or mild hyperglycemia\nand acidosis to severe hyperglycemia,diabetesjournals.org/care Diabetes Care in the Hospital S301\n©AmericanDiabetesAssociation | [
0.0010088870767503977,
0.019143318757414818,
-0.033870432525873184,
0.08012708276510239,
-0.027280045673251152,
0.0005547222099266946,
0.03054419346153736,
0.06751943379640579,
-0.03304985538125038,
-0.005461583379656076,
-0.017655178904533386,
0.04863165691494942,
-0.030828017741441727,
-... |
dehydration, and coma; therefore, indi-\nvidualization of treatment based on acareful clinical and laboratory assess-ment is needed (75,140 –142).\nManagement goals include restoration | [
-0.02366567961871624,
0.042965345084667206,
0.023489054292440414,
-0.03475962206721306,
-0.03272159770131111,
-0.0035238058771938086,
0.016424257308244705,
0.09992434829473495,
-0.05982388183474541,
-0.037486255168914795,
-0.01475459709763527,
-0.05359416827559471,
-0.03555947542190552,
0.... |
Management goals include restoration\nof circulatory volume and tissue perfusion,resolution of ketoacidosis, and correctionof electrolyte imbalance and acidosis. It isalso essential to treat any correctable un-derlying cause of DKA, such as sepsis, myo-cardial infarction, or stroke. In critically ill\nand mentally obtu... | [
-0.05834502726793289,
0.04476308450102806,
-0.013834790326654911,
-0.01856641285121441,
-0.09829822927713394,
0.00392759358510375,
-0.013696645386517048,
0.09092554450035095,
-0.05090637877583504,
0.019168054684996605,
0.012750746682286263,
-0.011131631210446358,
-0.08974651992321014,
0.06... |
and mentally obtunded individuals with\nDKA or HHS, continuous intravenous insu-lin is the standard of care. Successful transi-tion from intravenous to subcutaneousinsulin requires administration of basal in-sulin 2 –4 h before the intravenous insu- | [
-0.04074067622423172,
0.008193692192435265,
-0.11310198903083801,
-0.005317259579896927,
-0.07006122916936874,
-0.031448494642972946,
0.0342605821788311,
0.1374133974313736,
-0.06196901202201843,
-0.029780369251966476,
0.1003156378865242,
0.058426082134246826,
-0.020164992660284042,
0.0779... |
lin is stopped to prevent recurrence ofketoacidosis and rebound hyperglyce-mia (72,73,140). Recent studies havereported that the administration of alow dose of basal insulin analog in addi-\ntion to intravenous insulin infusion may\nprevent rebound hyperglycemia without in-creased risk of hypoglycemia (74 –76,140). | [
-0.0568014420568943,
-0.06007369980216026,
-0.06632291525602341,
0.0821533277630806,
0.05740571394562721,
0.04489438980817795,
0.08622895926237106,
0.0503004752099514,
-0.028487157076597214,
0.022262586280703545,
0.027439216151833534,
0.05480948090553284,
-0.07411035150289536,
-0.066953614... |
There is no signifi cant difference in out-\ncomes for intravenous human regularinsulin versus subcutaneous rapid-actinganalogs when combined with aggressivefluid management for treating mild or\nmoderate DKA (143). Individuals withuncomplicated DKA may sometimes betreated with subcutaneous rapid-acting\ninsulin analogs ... | [
0.010124243795871735,
-0.031109429895877838,
-0.02961592935025692,
0.0005147414631210268,
-0.06677471101284027,
-0.056960515677928925,
-0.024556037038564682,
0.1630854606628418,
-0.04434162750840187,
-0.05498230457305908,
0.049381744116544724,
0.039848413318395615,
-0.017364567145705223,
0... |
insulin analogs in the emergency depart-\nment or step-down units (144). This ap-proach may be safer and more cost-effective than treatment with intravenousinsulin. If subcutaneous insulin adminis-tration is used, it is important to providean adequate fluid replacement, frequent | [
-0.03963575139641762,
0.030002199113368988,
-0.08648216724395752,
-0.03947325050830841,
-0.030899634584784508,
-0.03773260861635208,
0.1005619466304779,
0.12218117713928223,
-0.021023936569690704,
-0.029981182888150215,
0.025486038997769356,
0.08196908980607986,
0.005196161102503538,
-0.00... |
POC blood glucose monitoring, treatmentof any concurrent infections, and appro-priate follow-up to avoid recurrent DKA.Several studies have shown that the useof bicarbonate in people with DKA\nmade no difference in the resolution | [
-0.008543433621525764,
0.07114504277706146,
-0.04225226864218712,
-0.032772552222013474,
-0.1368979662656784,
-0.016107356175780296,
0.07654674351215363,
0.13475941121578217,
0.024604156613349915,
-0.024600839242339134,
-0.06067090854048729,
-0.010162422433495522,
-0.1148383766412735,
0.05... |
made no difference in the resolution\nof acidosis or time to discharge, and itsuse is generally not recommended(145). For further treatment information,refer to recent in-depth reviews (53,107,146).\nTRANSITION FROM THE HOSPITAL\nTO THE AMBULATORY SETTING\nRecommendation\n16.14 A structured discharge plan\nshould be ta... | [
0.045242417603731155,
0.03228500112891197,
-0.00012941050226800144,
-0.010616146959364414,
-0.056968804448843,
0.019661638885736465,
-0.05325190722942352,
0.10440584272146225,
-0.005289820488542318,
-0.057049352675676346,
0.03552770987153053,
0.03864530846476555,
-0.005948628764599562,
0.0... |
should be tailored to the individual\nwith diabetes. BA structured discharge plan tailored to\nthe individual may reduce the length of\nhospital stay and readmission rates andincrease satisfaction with the hospital ex-perience (147). Multiple strategies arekey, including diabetes self-management\neducation prior to dis... | [
0.017431026324629784,
0.10005474835634232,
-0.010464097373187542,
0.0019768273923546076,
-0.09523322433233261,
0.08795063197612762,
0.054009225219488144,
0.025581592693924904,
-0.003409640397876501,
-0.022156568244099617,
-0.0029463095124810934,
0.040983885526657104,
-0.07866626232862473,
... |
education prior to discharge, diabetes\nmedication reconciliation with attentionto access, and scheduled virtual and/orface-to-face follow-up visits after discharge.Discharge planning should begin at admis-sion and be updated as individual needschange (148,149).\nThe transition from the acute care set- | [
-0.011692402884364128,
0.037108030170202255,
-0.01898639276623726,
-0.00022798977443017066,
-0.04555236175656319,
0.07280249148607254,
-0.035592883825302124,
0.00998432096093893,
-0.030640890821814537,
0.02470664493739605,
0.052407894283533096,
0.017790760844945908,
-0.10118597745895386,
0... |
The transition from the acute care set-\nting presents risks for all people with dia-betes. Individuals may be discharged tovaried settings, including home (with orwithout visiting nurse services), assistedliving, rehabilitation, or skilled nursing fa-cilities. For individuals discharged to home\nor assisted living, th... | [
-0.033138521015644073,
0.021958893164992332,
-0.02044186182320118,
0.0025034064892679453,
-0.032335903495550156,
0.07928460091352463,
0.02215910144150257,
0.01457020454108715,
-0.02662993036210537,
0.047570258378982544,
0.038295842707157135,
0.05577925965189934,
-0.04011701047420502,
0.042... |
or assisted living, the optimal discharge\nplan will need to consider diabetes typeand severity, effects of the illness on bloodglucose levels, and the individual ’sc i r -\ncumstances, capabilities, and preferen-ces (21,150,151). See Section 13, “Older\nAdults, ”for more information.\nAn outpatient follow-up visit wit... | [
0.03641325235366821,
0.044293854385614395,
-0.027960533276200294,
0.03431350365281105,
-0.07595828920602798,
0.04656018316745758,
-0.0035308990627527237,
0.06855641305446625,
-0.07390931993722916,
0.014474164694547653,
-0.007987300865352154,
0.020161209627985954,
-0.05792352557182312,
0.09... |
Adults, ”for more information.\nAn outpatient follow-up visit with the\nprimary care clinician, endocrinologist, ordiabetes care and education specialistwithin 1 month of discharge is advised forall individuals experiencing hyperglycemiaand/or hypoglycemia in the hospital. If gly-cemic medications are changed or glucos... | [
0.028595929965376854,
0.04551566392183304,
-0.010328240692615509,
0.03472024202346802,
-0.07515078037977219,
-0.054277632385492325,
0.01635373756289482,
0.030876770615577698,
-0.00493643106892705,
-0.027456285431981087,
-0.011051364243030548,
0.02138032577931881,
-0.12977547943592072,
-0.0... |
management is not optimal at discharge,\nan earlier appointment (in 1 –2 weeks) is\npreferred, and frequent contact may beneeded to avoid hyperglycemia and hypo-glycemia. A discharge algorithm for gly-cemic medication adjustment, based onadmission A1C, diabetes medications be-\nfore admission, and insulin usage during | [
-0.022200357168912888,
0.044069986790418625,
-0.013221809640526772,
-0.00846281461417675,
-0.07563738524913788,
-0.026975123211741447,
0.03083745390176773,
0.07330096513032913,
-0.016296207904815674,
-0.038276731967926025,
0.002027566311880946,
0.062016475945711136,
-0.0356290228664875,
0.... |
fore admission, and insulin usage during\nhospitalization was found useful to guidetreatment decisions and signi ficantly im-\nprove A1C after discharge (4).\nClear communication with outpatient\nhealth care professionals directly or viahospital discharge summaries facilitates\nsafe transitions to outpatient care. Provi... | [
-0.020521126687526703,
0.041226405650377274,
-0.007459019776433706,
0.004474184941500425,
0.007673169020563364,
0.0346701517701149,
0.06896455585956573,
0.0703202337026596,
0.01882428675889969,
-0.008242670446634293,
-0.02375900186598301,
0.0035395969171077013,
-0.03636786714196205,
0.0323... |
safe transitions to outpatient care. Provid-\ning information regarding the root causeof hyperglycemia (or the plan for determin-ing the cause), related complications andcomorbidities, and recommended treat-ments can assist outpatient health careprofessionals as they assume ongoing care.\nThe Agency for Healthcare Rese... | [
-0.0458606481552124,
0.009133830666542053,
-0.04802025482058525,
-0.004700787365436554,
-0.036947101354599,
0.01671239174902439,
0.016705593094229698,
0.09007885307073593,
-0.03924501687288284,
-0.02819780260324478,
-0.015234969556331635,
0.046974122524261475,
-0.08003849536180496,
-0.0341... |
The Agency for Healthcare Research\nand Quality recommends that, at a min-imum, discharge plans include the fol-lowing (152):Medication Reconciliation\n\x81Home and hospital medications mustbe cross-checked to ensure that nochronic medications are stopped andto ensure the safety of new and oldprescriptions. | [
-0.0024695780593901873,
0.042872220277786255,
0.01104069035500288,
-0.028783805668354034,
-0.052677080035209656,
-0.0028131860308349133,
-0.0227094404399395,
0.13212817907333374,
0.09837808459997177,
-0.03579922392964363,
0.03210851177573204,
0.04680376872420311,
-0.019686298444867134,
0.0... |
\x81Prescriptions for new or changed medi-cation should be filled and reviewed\nwith the individual and care partners ator before discharge.\nStructured Discharge\nCommunication\n\x81I n f o r m a t i o no nm e d i c a t i o nc h a n g e s , | [
-0.021940020844340324,
0.03892188519239426,
0.003500026185065508,
-0.061576660722494125,
-0.06604523956775665,
0.06868350505828857,
0.02018790692090988,
0.09133697301149368,
-0.014203706756234169,
-0.010549264959990978,
0.03040756657719612,
-0.0224996879696846,
-0.06497924029827118,
0.0688... |
\x81I n f o r m a t i o no nm e d i c a t i o nc h a n g e s ,\npending tests and studies, and follow-upneeds must be accurately and promptlycommunicated to outpatient health careprofessionals.\n\x81Discharge summaries should be trans-mitted to the primary care clinician assoon as possible after discharge. | [
-0.04091153293848038,
0.061481986194849014,
-0.016788171604275703,
-0.010944584384560585,
-0.05693521723151207,
0.03536016494035721,
0.03590213507413864,
0.10980787873268127,
0.00469612330198288,
-0.03079478070139885,
0.0599772073328495,
-0.025056948885321617,
0.00543082132935524,
0.082679... |
\x81Scheduling follow-up appointmentsprior to discharge with people with dia-betes agreeing to the time and placeincreases the likelihood that they willattend.\nIt is recommended that the followingareas of knowledge be reviewed and ad-dressed before hospital discharge:\n\x81Identi fication of the health care profes-\nsi... | [
-0.06732174754142761,
0.07346056401729584,
0.002559236716479063,
0.009089009836316109,
-0.08840011060237885,
0.07172909379005432,
0.10345407575368881,
0.018889572471380234,
-0.031618837267160416,
-0.045495372265577316,
0.018727600574493408,
0.006868904456496239,
-0.05440510809421539,
0.055... |
sionals who will provide diabetes care\nafter discharge.\n\x81Level of understanding related to thediabetes diagnosis, glucose monitoring,home glucose goals, and when to call ahealth care professional.\n\x81Definition, recognition, treatment, and\nprevention of hyperglycemia andhypoglycemia. | [
-0.01959080435335636,
0.022489581257104874,
-0.016815312206745148,
-0.004338790662586689,
-0.06657720357179642,
-0.01369741652160883,
0.1294703185558319,
0.06521350145339966,
-0.034530457109212875,
-0.04629473760724068,
-0.07294768840074539,
-0.022514497861266136,
-0.11117607355117798,
-0.... |
prevention of hyperglycemia andhypoglycemia.\n\x81Information on making healthy foodc h o i c e sa th o m ea n dr e f e r r a lt oa no u t -patient registered dietitian nutritionistor diabetes care and education special-ist to guide individualization of themeal plan, if needed. | [
-0.04446626082062721,
0.10658257454633713,
0.028904134407639503,
0.005990579258650541,
-0.07951706647872925,
0.09156056493520737,
0.021772492676973343,
0.060556791722774506,
-0.06785622239112854,
0.002227567369118333,
-0.026574719697237015,
0.03679979592561722,
-0.10127946734428406,
-0.112... |
\x81When and how to take blood glu-cose-lowering medications, includinginsulin administration and noninsulininjectables.\n\x81Sick-day management (21,151).\n\x81Proper use and disposal of diabetessupplies, e.g., insulin pen, pen needles,syringes, and lancets.\nPeople with diabetes must be pro- | [
-0.01940068230032921,
0.06884417682886124,
-0.0004686143365688622,
0.03238745406270027,
-0.05229347571730614,
-0.018335582688450813,
0.10509293526411057,
0.13381966948509216,
-0.11683078855276108,
-0.04657270386815071,
-0.03008255921304226,
0.03533260524272919,
-0.06898324936628342,
0.0221... |
People with diabetes must be pro-\nvided with appropriate durable medicalequipment, medications, supplies (e.g.,blood glucose test strips or CGMS302 Diabetes Care in the Hospital Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
-0.04491032660007477,
0.021686071529984474,
-0.0586780309677124,
-0.02507283352315426,
-0.023088566958904266,
0.07086622714996338,
0.09026575833559036,
0.09604286402463913,
-0.03778356686234474,
0.020977111533284187,
-0.0039981030859053135,
0.019477805122733116,
-0.1244475394487381,
0.0326... |
sensors), prescriptions, and appropriate\neducation at the time of discharge to\navoid a potentially dangerous hiatus in\ncare.\nPREVENTING ADMISSIONS AND\nREADMISSIONS\nIn people with diabetes, the hospital read-\nmission rate is between 14% and 20%,\nwhich is nearly twice that in people with- | [
0.04637589305639267,
0.02237381413578987,
-0.0028725352603942156,
-0.0004389029636513442,
0.003358524991199374,
0.044376201927661896,
0.060922496020793915,
0.053887151181697845,
-0.010506857186555862,
-0.012192392721772194,
-0.005551857873797417,
0.06947721540927887,
-0.08586908131837845,
... |
which is nearly twice that in people with-\nout diabetes (148,153). This may result inincreased diabetes distress and has signi fi-\ncantfinancial implications. Of people with\ndiabetes who are hospitalized, 30% have\ntwo or more hospital stays, and these ad-\nmissions account for over 50% of hospitalcosts for diabetes (... | [
0.06939373910427094,
0.01917210966348648,
-0.06035962328314781,
0.03520747274160385,
-0.021042386069893837,
-0.0013788017677143216,
0.08743774890899658,
0.09289899468421936,
-0.013277044519782066,
-0.056994132697582245,
0.021734321489930153,
0.0333421416580677,
-0.03825617581605911,
0.0472... |
ing to readmission include male sex,\nlonger duration of prior hospitalization,number of previous hospitalizations, num-\nber and severity of comorbidities, and\nlower socioeconomic and/or educationalstatus; factors that may reduce readmis-\nsion rates include scheduled home health\nvisits and timely ambulatory follow-... | [
0.11208157986402512,
0.01754184439778328,
-0.024231715127825737,
-0.0086051682010293,
-0.036844830960035324,
0.10220056027173996,
-0.029130063951015472,
0.08339719474315643,
-0.02561919204890728,
-0.003836835501715541,
0.006717029493302107,
0.032103583216667175,
-0.001939074951224029,
0.01... |
visits and timely ambulatory follow-up\ncare (148,153). While there is no standard\nto prevent readmissions, several successfulstrategies have been reported that identify\nhigh-risk individuals and offer some possi-\nble solutions (148). These include reachingout to people with ketosis-prone diabetes\n(155), insulin tr... | [
0.023873768746852875,
0.06909412890672684,
-0.014011995866894722,
0.021282803267240524,
-0.07013590633869171,
0.052754029631614685,
0.08813825994729996,
0.06429391354322433,
-0.041834913194179535,
-0.059061840176582336,
0.008690526708960533,
0.07462608069181442,
-0.032652597874403,
0.02447... |
(155), insulin treatment of individuals with\nadmission A1C >9% (>75 mmol/mol)\n(156), and the use of a transitional caremodel (157). For people with diabetickidney disease, collaborative person-\ncentered medical homes may decrease\nrisk-adjusted readmission rates (158).\nA g ei sa l s oa ni m p o r t a n tr i s kf a ... | [
0.001104352530092001,
0.01842876523733139,
-0.05084177479147911,
0.012965057045221329,
-0.06802600622177124,
-0.010581252165138721,
0.06022007390856743,
0.07686690241098404,
-0.033118944615125656,
-0.050473835319280624,
-0.007510357536375523,
0.08109249919652939,
-0.03335432708263397,
-0.0... |
A g ei sa l s oa ni m p o r t a n tr i s kf a c t o ri n\nhospitalization and readmission among\npeople with diabetes (refer to Section 13,\n“Older Adults, ”for detailed criteria). Suc-\ncessful proactive care transitions from in-\npatient to outpatient is a key strategy for\npreventing readmission.\nReferences | [
0.032948438078165054,
0.005697185639292002,
-0.06303408741950989,
0.008950542658567429,
-0.06582338362932205,
0.05057239159941673,
0.05721975490450859,
0.07372381538152695,
-0.03768172487616539,
-0.0473269522190094,
-0.011075458489358425,
0.12129247188568115,
-0.030772563070058823,
-0.0147... |
preventing readmission.\nReferences\n1 . S e i s aM O ,S a a d iS ,N a y f e hT ,e ta l .As y s t e m a t i c\nreview supporting the Endocrine Society clinical\npractice guideline for the management of\nhyperglycemia in adults hospitalized for noncritical\nillness or undergoing elective surgical procedures. J\nClin End... | [
0.014991629868745804,
0.03868241608142853,
-0.026749160140752792,
0.0197919774800539,
-0.005348264705389738,
0.10521499067544937,
0.05551233887672424,
0.11333175748586655,
-0.04041478782892227,
0.004859822802245617,
-0.06038079038262367,
0.08373819291591644,
-0.09364340454339981,
0.0043271... |
Clin Endocrinol Metab 2022;107:2139– 2147\n2. ElSayed NA, Aleppo G, Aroda VR, et al.\nAmerican Diabetes Association. 16. Diabetes care\nin the hospital: S t a n d a r d so fC a r ei nD i a b e t e s —\n2023 . Diabetes Care 2023;46(Suppl. 1):S267 –S278\n3. Pasquel FJ, Gomez-Huelgas R, Anzola I, et al.\nPredictive value ... | [
0.009039838798344135,
0.006965847685933113,
-0.07686642557382584,
-0.03664436563849449,
-0.004063078667968512,
0.004175031092017889,
0.07918784767389297,
0.1313755065202713,
-0.015293688513338566,
-0.02275266870856285,
-0.10478340089321136,
0.019586127251386642,
-0.1458856463432312,
-0.010... |
Predictive value of admission hemoglobin A1c on\ninpatient glycemic control and response to insulin\ntherapy in medicine and surgery patients with type 2\ndiabetes. Diabetes Care 2015;38:e202– e2034. Umpierrez GE, Reyes D, Smiley D, et al.\nHospital discharge algorithm based on admission | [
-0.011813375167548656,
0.011911805719137192,
-0.04730164632201195,
0.0005040437099523842,
-0.01608670875430107,
-0.006169889122247696,
0.05374304950237274,
0.07356158643960953,
-0.022513490170240402,
0.011870410293340683,
-0.08603420853614807,
0.03251387178897858,
-0.05203273147344589,
-0.... |
Hospital discharge algorithm based on admission\nHbA1c for the management of patients with type2 diabetes. Diabetes Care 2014;37:2934 –2939\n5. Carpenter DL, Gregg SR, Xu K, Buchman TG,Coopersmith CM. Prevalence and impact ofunknown diabetes in the ICU. Crit Care Med2015;43:e541– e550 | [
0.004191297572106123,
0.035504866391420364,
-0.021374206990003586,
-0.0011096833040937781,
-0.04240201786160469,
0.026383446529507637,
0.008736729621887207,
0.046324413269758224,
0.00720152398571372,
-0.025519337505102158,
-0.0401509590446949,
0.013611849397420883,
-0.007536374032497406,
0... |
6. Nanayakkara N, Nguyen H, Churilov L, et al.Inpatient HbA1c testing: a prospective observational\nstudy. BMJ Open Diabetes Res Care 2015;3:e000113\n7. Nassar CM, Montero A, Magee MF. Inpatient\ndiabetes education in the real world: an overviewof guidelines and delivery models. Curr Diab Rep2019;19:103\n8. Garg R, Sch... | [
-0.03281107917428017,
-0.02649495005607605,
-0.06006845459342003,
0.03961845114827156,
-0.07080741971731186,
0.009791052900254726,
-0.009978226386010647,
0.07805097848176956,
-0.017302151769399643,
-0.025058068335056305,
-0.044810254126787186,
0.026214634999632835,
-0.0201560165733099,
-0.... |
8. Garg R, Schuman B, Bader A, et al. Effect of\npreoperative diabetes management on glycemiccontrol and clinical outcomes after elective surgery.Ann Surg 2018;267:858– 862\n9. van den Boom W , Schroeder RA, Manning\nMW , Setji TL, Fiestan GO, Dunson DB. Effect of | [
-0.047104235738515854,
0.038498662412166595,
-0.03983043134212494,
0.05794639512896538,
-0.016840148717164993,
0.037265557795763016,
0.027315402403473854,
0.05200653895735741,
-0.04860584810376167,
-0.02097000926733017,
-0.04928748309612274,
0.14538848400115967,
-0.02843768708407879,
-0.04... |
MW , Setji TL, Fiestan GO, Dunson DB. Effect of\nA1C and glucose on postoperative mortality innoncardiac and cardiac surgeries. Diabetes Care2018;41:782– 788 | [
-0.1037915050983429,
0.003493735333904624,
-0.07257166504859924,
0.03423227369785309,
-0.04172004014253616,
-0.017658492550253868,
0.03572605550289154,
0.0630972608923912,
-0.037166014313697815,
-0.01456768624484539,
-0.04780890420079231,
0.0552971176803112,
-0.06102475896477699,
0.0169916... |
10. Setji T, Hopkins TJ, Jimenez M, et al.Rationalization, development, and implementationof a preoperative diabetes optimization programdesigned to improve perioperative outcomes andreduce cost. Diabetes Spectr 2017;30:217 –223 | [
-0.0010687151225283742,
0.07358121871948242,
0.009772512130439281,
0.00033820499083958566,
-0.07694655656814575,
0.025758706033229828,
0.012335325591266155,
0.06567442417144775,
0.0022727681789547205,
0.019423963502049446,
-0.11087439209222794,
0.03787693381309509,
-0.04512501135468483,
-0... |
11. Okabayashi T, Shima Y, Sumiyoshi T, et al.Intensive versus intermediate glucose control insurgical intensive care unit patients. DiabetesCare 2014;37:1516– 1524\n12. Institute of Medicine. Preventing Medication\nErrors. Aspden P, Wolcott J, Bootman JL,\nCronenwett LR, Eds. Washington, DC, NationalAcademies Press, 2... | [
-0.05726106837391853,
0.05304323881864548,
-0.049154072999954224,
0.019664034247398376,
-0.039415858685970306,
0.00879290234297514,
-0.03575935587286949,
0.08855058252811432,
-0.02617632783949375,
-0.039568495005369186,
-0.04144269600510597,
0.065039724111557,
-0.03620956838130951,
0.02541... |
Cronenwett LR, Eds. Washington, DC, NationalAcademies Press, 2007\n13. Sly B, Russell AW , Sullivan C. Digital inter-\nventions to improve safety and quality of\ninpatient diabetes management: a systematicreview. Int J Med Inform 2022;157:104596\n14. Nguyen M, Jankovic I, Kalesinskas L, Baiocchi | [
-0.041977424174547195,
0.02672954462468624,
-0.0723709911108017,
0.020980525761842728,
-0.03296646848320961,
0.042262185364961624,
0.041010525077581406,
0.10238420218229294,
-0.03191506862640381,
0.02619127929210663,
-0.04203655198216438,
0.07705269008874893,
-0.034116391092538834,
0.00398... |
14. Nguyen M, Jankovic I, Kalesinskas L, Baiocchi\nM, Chen JH. Machine learning for initial insulinestimation in hospitalized patients. J Am MedInform Assoc 2021;28:2212– 2219\n1 5 . A k i b o y eF ,S i h r eH K ,A lM u l h e mM ,R a y m a nG, Nirantharakumar K, Adderley NJ. Impact of\ndiabetes specialist nurses on inp... | [
-0.0377538800239563,
0.002811025595292449,
-0.07946007698774338,
0.06902983039617538,
0.012820340692996979,
0.042386773973703384,
0.04495595395565033,
0.047741882503032684,
-0.060575906187295914,
-0.06240734085440636,
-0.0938110500574112,
0.13253197073936462,
-0.046007946133613586,
0.01718... |
diabetes specialist nurses on inpatient care: a\nsystematic review. Diabet Med 2021;38:e14573\n16. Wang YJ, Seggelke S, Hawkins RM, et al.\nImpact of glucose management team on outcomesof hospitalizaron in patients with type 2 diabetesadmitted to the medical service. Endocr Pract2016;22:1401– 1405 | [
-0.04234755039215088,
0.019135504961013794,
-0.06320787221193314,
0.041293758898973465,
-0.07266212999820709,
-0.009821523912250996,
0.03290583938360214,
0.03269544243812561,
-0.004428443498909473,
-0.0788978636264801,
-0.09290486574172974,
0.08211476355791092,
-0.09942594915628433,
0.0719... |
17. Bansal V, Mottalib A, Pawar TK, et al.Inpatient diabetes management by specializeddiabetes team versus primary service team in non-\ncritical care units: impact on 30-day readmission\nrate and hospital cost. BMJ Open Diabetes ResCare 2018;6:e000460\n18. Ostling S, Wyckoff J, Ciarkowski SL, et al. The | [
-0.01158418133854866,
0.013492771424353123,
-0.012492816895246506,
0.03246760740876198,
-0.05082959309220314,
0.054071687161922455,
-0.013830495998263359,
0.11031635105609894,
0.01985265128314495,
-0.011511472053825855,
-0.0634341761469841,
0.049430690705776215,
-0.03047877736389637,
0.009... |
18. Ostling S, Wyckoff J, Ciarkowski SL, et al. The\nrelationship between diabetes mellitus and 30-day readmission rates. Clin Diabetes Endocrinol2017;3:3\n19. Rushakoff RJ, Sullivan MM, MacMaster HW,\net al. Association between a virtual glucose\nmanagement service and glycemic control in | [
0.0011128378100693226,
-0.006597134750336409,
-0.0666733831167221,
0.0009957862785086036,
-0.030166734009981155,
0.025966843590140343,
0.05726386234164238,
0.08830516040325165,
-0.006205884739756584,
-0.031557224690914154,
-0.040942203253507614,
0.0764898732304573,
-0.07837499678134918,
-0... |
management service and glycemic control in\nhospitalized adult patients: an observational study.Ann Intern Med 2017;166:621– 627\n20. Magee MF, Baker KM, Bardsley JK, WesleyD, Smith KM. Diabetes to go-inpatient: pragmaticlessons learned from implementation of technology-enabled diabetes survival skills education within | [
0.0016839768504723907,
0.05157000571489334,
-0.05225500464439392,
0.042048387229442596,
-0.047876402735710144,
0.033443424850702286,
0.06433158367872238,
0.04802802577614784,
-0.04736548289656639,
-0.009697431698441505,
-0.06014440581202507,
0.10693930089473724,
-0.03814072534441948,
-0.02... |
nursing unit workfl ow in an urban, tertiary care\nhospital. Jt Comm J Qual Patient Saf 2021;47:\n107– 119\n21. Pinkhasova D, Swami JB, Patel N, et al.\nPatient understanding of discharge instructionsfor home diabetes self-management and risk for\nhospital readmission and emergency department\nvisits. Endocr Pract 2021;... | [
-0.010681645013391972,
0.01634928770363331,
-0.06735391169786453,
0.03195511922240257,
-0.01407352089881897,
0.05956733226776123,
0.06112498790025711,
0.021372893825173378,
-0.006671164184808731,
-0.034621093422174454,
-0.03946458175778389,
0.044872138649225235,
-0.061967503279447556,
0.08... |
visits. Endocr Pract 2021;27:561– 566\n22. Society of Hospital Medicine. Glycemiccontrol for hospitalists. Accessed 21 August 2023.Available from https://www.hospitalmedicine.org/clinical-topics/glycemic-control/\n23. Arnold P, Scheurer D, Dake AW, et al.\nHospital guidelines for diabetes management | [
-0.000630426628049463,
0.00486505962908268,
-0.05598481371998787,
0.049405600875616074,
-0.06437902897596359,
0.01273246482014656,
0.001515126321464777,
0.07308085262775421,
-0.061385270208120346,
0.0004711920046247542,
-0.025363245978951454,
0.05943780019879341,
-0.10767973214387894,
-0.0... |
Hospital guidelines for diabetes management\nand the Joint Commission-American DiabetesAssociation Inpatient Diabetes Certi fication. Am J\nMed Sci 2016;351:333– 341\n24. Association of British Diabetologists. JointBritish Diabetes Societies (JBDS) for Inpatient\nCare Group. Accessed 21 August 2023. Available\nfrom http... | [
-0.016080906614661217,
-0.009871259331703186,
-0.03525550290942192,
0.02348431572318077,
-0.0919756293296814,
0.04669608920812607,
0.008022681809961796,
0.021694593131542206,
-0.05091315880417824,
-0.07564521580934525,
-0.061345987021923065,
0.04173751175403595,
-0.04955168068408966,
0.029... |
from https://abcd.care/jbds-ip\n25. Agiostratidou G, Anhalt H, Ball D, et al.\nStandardizing clinically meaningful outcomemeasures beyond HbA\n1cfor type 1 diabetes: a\nconsensus report of the American Association ofClinical Endocrinologists, the American Association\nof Diabetes Educators, the American Diabetes | [
-0.05017336085438728,
0.03439473360776901,
-0.0628717690706253,
0.07133366912603378,
-0.07254388183355331,
0.026558587327599525,
0.0416911318898201,
0.10601914674043655,
-0.06795613467693329,
-0.05280360206961632,
-0.0683818906545639,
0.06447068601846695,
-0.10091111809015274,
-0.054945416... |
of Diabetes Educators, the American Diabetes\nAssociation, the Endocrine Society, JDRF International,The Leona M. and Harry B. Helmsley Charitable Trust,the Pediatric Endocrine Society, and the T1DExchange. Diabetes Care 2017;40:1622– 1630\n26. Cardona S, Gomez PC, Vellanki P , et al.\nClinical characteristics and outc... | [
0.04108457639813423,
0.05615725740790367,
-0.06488451361656189,
0.08014024794101715,
-0.05267399922013283,
-0.01208573393523693,
0.008555717766284943,
0.023787157610058784,
-0.026342760771512985,
-0.005040617659687996,
-0.048104558140039444,
0.07125723361968994,
-0.13173407316207886,
0.007... |
Clinical characteristics and outcomes of\nsymptomatic and asymptomatic hypoglycemiain hospitalized patients with diabetes. BMJOpen Diabetes Res Care 2018;6:e000607\n27. Van den Berghe G, Wouters P , Weekers F,\net al. Intensive insulin therapy in critically ill\npatients. N Engl J Med 2001;345:1359– 1367 | [
0.006900399457663298,
0.04507160186767578,
-0.10439067333936691,
0.08281372487545013,
-0.05966891720890999,
0.012622283771634102,
0.03782551735639572,
0.0879015177488327,
-0.06285716593265533,
-0.0295297559350729,
-0.08725086599588394,
0.03092675283551216,
-0.04364999011158943,
0.011095712... |
patients. N Engl J Med 2001;345:1359– 1367\n28. Finfer S, Chittock DR, Su SY , et al.; NICE-\nSUGAR Study Investigators. Intensive versusconventional glucose control in critically illpatients. N Engl J Med 2009;360:1283 –1297\n29. Kansagara D, Fu R, Freeman M, Wolf F,Helfand M. Intensive insulin therapy in hospitalized | [
-0.04623054713010788,
-0.004662463441491127,
-0.11842940002679825,
0.03433224558830261,
-0.04111698269844055,
-0.0111400680616498,
0.005930451210588217,
0.12054572254419327,
-0.03310414403676987,
0.026778381317853928,
-0.06750551611185074,
0.05121889337897301,
-0.05606143921613693,
0.04907... |
patients: a systematic review. Ann Intern Med\n2011;154:268– 282\n30. Sathya B, Davis R, Taveira T, Whitlatch H, WuWC. Intensity of peri-operative glycemic controland postoperative outcomes in patients withdiabetes: a meta-analysis. Diabetes Res Clin Pract\n2013;102:8 –15\n31. Umpierrez G, Cardona S, Pasquel F, et al. | [
0.0016992491437122226,
0.015627842396497726,
-0.06701342016458511,
0.02621825598180294,
-0.11622962355613708,
-0.01496898289769888,
-0.011644418351352215,
0.0999961718916893,
0.0036235020961612463,
-0.03145716339349747,
-0.0705219954252243,
0.1022709384560585,
-0.08790522813796997,
-0.0024... |
2013;102:8 –15\n31. Umpierrez G, Cardona S, Pasquel F, et al.\nRandomized controlled trial of intensive versusconservative glucose control in patients undergoingcoronary artery bypass graft surgery: GLUCO-CABGtrial. Diabetes Care 2015;38:1665 –1672\n32. Furnary AP , Wu Y , Bookin SO. Effect of\nhyperglycemia and contin... | [
-0.08326730132102966,
0.029371436685323715,
-0.06373841315507889,
0.05703078955411911,
-0.041523635387420654,
-0.004132330417633057,
0.014356696046888828,
0.0558629110455513,
-0.009636690840125084,
0.015277520753443241,
-0.04650939255952835,
0.08010610193014145,
-0.04542487859725952,
-0.02... |
hyperglycemia and continuous intravenous insulin\ninfusions on outcomes of cardiac surgical procedures:the Portland Diabetic Project. Endocr Pract 2004;10(Suppl. 2):21 –33\n33. Magaji V, Nayak S, Donihi AC, et al.Comparison of insulin infusion protocols targeting110-140 mg/dL in patients after cardiac surgery. | [
-0.02131907269358635,
0.059587061405181885,
-0.08576700836420059,
0.021176965907216072,
-0.03303524851799011,
-0.05720674991607666,
0.018396394327282906,
0.020470812916755676,
-0.01946725882589817,
-0.004681053571403027,
-0.051119085401296616,
0.07179103046655655,
-0.06909409165382385,
0.0... |
Diabetes Technol Ther 2012;14:1013 –1017\n34. Flory JH, Aleman JO, Furst J, Seley JJ. Basal\ninsulin use in the non-critical care setting: isfasting hypoglycemia inevitable or preventable? JDiabetes Sci Technol 2014;8:427– 428diabetesjournals.org/care Diabetes Care in the Hospital S303\n©AmericanDiabetesAssociation | [
-0.04222694784402847,
-0.0267013106495142,
-0.09841028600931168,
0.04567413777112961,
-0.008583744056522846,
0.02690768986940384,
0.06723873317241669,
0.046540580689907074,
-0.04386153072118759,
-0.06143520027399063,
-0.02622365951538086,
0.1097702905535698,
-0.05194803699851036,
-0.002557... |
17. Diabetes Advocacy: Standards\nof Care in Diabetes— 2024\nDiabetes Care 2024;47(Suppl. 1):S307 –S308 |https://doi.org/10.2337/dc24-S017American Diabetes Association\nProfessional Practice Committee *\nThe American Diabetes Association (ADA) “Standards of Care in Diabetes ”includes | [
-0.020616332069039345,
0.01671307347714901,
-0.08006120473146439,
0.04174278676509857,
-0.004771452397108078,
0.05910399183630943,
-0.0010505677200853825,
0.00193385302554816,
-0.08368325978517532,
-0.0426519401371479,
-0.07597644627094269,
0.07405519485473633,
-0.13824015855789185,
-0.023... |
the ADA ’s current clinical practice recommendations and is intended to provide the\ncomponents of diabetes care, general treatment goals and guidelines, and tools to | [
-0.04139997065067291,
0.0067419796250760555,
-0.08455739915370941,
0.06411178410053253,
-0.05609036609530449,
0.022022750228643417,
0.043380189687013626,
0.06556293368339539,
-0.0767926424741745,
-0.07625574618577957,
-0.05552008002996445,
0.04925420135259628,
-0.11957837641239166,
0.03734... |
evaluate quality of care. Members of the ADA Professional Practice Committee, aninterprofessional expert committee, are responsible for updating the Standards ofCare annually, or more frequently as warranted. For a detailed description of ADA\nstandards, statements, and reports, as well as the evidence-grading system f... | [
-0.04984254390001297,
-0.05228807032108307,
-0.05165698751807213,
0.07347115129232407,
-0.06794809550046921,
0.007086051627993584,
0.003268467728048563,
0.04484937712550163,
-0.06499830633401871,
0.02566898986697197,
-0.04950512573122978,
-0.005689178127795458,
-0.07334770262241364,
0.0067... |
clinical practice recommendations and a full list of Professional Practice Committee\nmembers, please refer to Introduction and Methodology. Readers who wish to com-ment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.\nManaging the daily health demands of diabetes can be challenging. Peo... | [
0.009496261365711689,
-0.002206715289503336,
-0.03281944990158081,
0.0481845997273922,
-0.08736827969551086,
-0.0004560773668345064,
0.014038082212209702,
0.08947690576314926,
-0.044846851378679276,
-0.02794298343360424,
-0.1270633488893509,
0.030177999287843704,
-0.11992999911308289,
0.02... |
with diabetes should not have to face discrimination due to diabetes. By advocatingfor the rights of those with diabetes at all levels, the American Diabetes Association(ADA) can help to ensure that they live a healthy and productive life. A strategic goalof the ADA is for more children and adults with diabetes to live... | [
-0.06862721592187881,
0.06938052177429199,
-0.08399184048175812,
0.03770589828491211,
0.004273765720427036,
0.08449777215719223,
0.13370411098003387,
-0.0508948378264904,
-0.030357232317328453,
-0.04353617876768112,
-0.030687415972352028,
0.05600682646036148,
-0.1059960126876831,
-0.002841... |
more children and adults with diabetes to live free from the burdenof discrimination. The ADA is also focused on making sure cost is not a barrier to suc-cessful diabetes management. | [
-0.058180201798677444,
0.0571524016559124,
-0.042748790234327316,
0.07546139508485794,
0.08149346709251404,
0.09093482047319412,
0.08235077559947968,
0.0027508263010531664,
0.01874179020524025,
0.002098338445648551,
-0.034796833992004395,
0.021500956267118454,
-0.06683067977428436,
-0.0088... |
One tactic for achieving these goals has been to implement the ADA Standards of | [
-0.06928595900535583,
0.006930265575647354,
-0.06839866191148758,
-0.021641308441758156,
-0.02253539115190506,
0.06737473607063293,
0.028563953936100006,
0.01580691523849964,
-0.1205844059586525,
-0.025540508329868317,
-0.014513954520225525,
0.015092235058546066,
-0.018108099699020386,
0.0... |
Care through advocacy-oriented position statements. The ADA publishes evidence-based, peer-reviewed statements on topics such as diabetes and employment, diabe-tes and driving, insulin access and affordability, and diabetes management in certainsettings such as schools, childcare programs, and detention facilities. In ... | [
-0.04903460666537285,
0.057166267186403275,
-0.055406779050827026,
0.08694366365671158,
0.003773856209591031,
0.08140305429697037,
0.0903625562787056,
0.021509822458028793,
-0.041010260581970215,
-0.028455330058932304,
-0.035628706216812134,
0.07756964862346649,
-0.07945753633975983,
0.027... |
programs, and detention facilities. In addition to theADA’ s clinical documents, these advocacy statements are important tools in educating | [
-0.00682994956150651,
0.11416832357645035,
-0.0372854620218277,
0.015430565923452377,
-0.010520721785724163,
0.11040834337472916,
0.004735266324132681,
0.04069240763783455,
0.03596225380897522,
0.0032517029903829098,
0.07990149408578873,
0.08194221556186676,
-0.04977548122406006,
0.0398821... |
schools, employers, licensing agencies, policy makers, and others about the intersec-tion of diabetes management and the law and for providing scienti fically supported\npolicy recommendations.\nADVOCACY STATEMENTS | [
-0.004495599307119846,
0.050724711269140244,
-0.009763157926499844,
0.03731163963675499,
-0.01424462627619505,
0.009429891593754292,
-0.005100196227431297,
0.039895232766866684,
-0.021811727434396744,
-0.005470059346407652,
-0.027520591393113136,
0.06061930954456329,
-0.10617100447416306,
... |
policy recommendations.\nADVOCACY STATEMENTS\nThe following is a partial list of advocacy statements ordered by publication date, withthe most recent statement appearing first. A comprehensive list of advocacy state-\nments is available at professional.diabetes.org/content/key-statements-and-reports. | [
0.04827818647027016,
0.1117880567908287,
-0.01667952910065651,
0.04894319549202919,
0.009092041291296482,
0.10003930330276489,
0.0667174756526947,
0.037850938737392426,
-0.04393192008137703,
-0.01818048767745495,
-0.044364769011735916,
0.06273767352104187,
-0.059594884514808655,
0.00863544... |
Care of Young Children With Diabetes in the Childcare and Community\nSetting\nVery young children (aged <5 years) with diabetes have legal protections and can be\nsafely cared for by childcare professionals with appropriate training, access to resour-\nces, and a communication system with parents/guardians and the chil... | [
-0.054060012102127075,
0.07893387228250504,
-0.02447241172194481,
0.02735353261232376,
-0.055576153099536896,
0.06276285648345947,
0.06363477557897568,
0.014915060251951218,
-0.011963940225541592,
0.01645822823047638,
0.01208201888948679,
0.027551494538784027,
-0.08019344508647919,
0.03375... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.